General Information
Novo-Nordisk SUSTAIN 3623
Efficacy and Safety of semaglutide once weekly versus placebo in drug-naive subjects with type 2 diabetes
| Protocol | NN9535-3623 |
|---|---|
| Identifier | NN9535-3623 Site Number 421 V#1157252 |
| UID | 93e454b8-9b77-4754-a83c-abb9eec33636 |
| Status | Done - Archived |
| Phase | 3a |
| Category | Diabetes Type 2 / Adult |
| Launch Year | 2014 |
| NCT Number | - |
| Created | 2013-09-10 16:38 |
| Last Updated | 2013-09-10 16:38 |
Description
No description provided.
Comment
No comment.
Target Dates
| Name | Date | Required |
|---|---|---|
| Enrollment Closed | 2014-09-01 | No |
| Enrollment Open | No | |
| First Patient First Visit | No | |
| Site Initiation Mtg. | 2014-01-06 | No |
| PI Meeting Start | 2013-10-24 | No |
| PI Meeting End | 2013-10-25 | No |
| PI Meeting Arrival | No | |
| PI Meeting Departure | No | |
| Closeout Date | 2015-07-01 | No |
| Final PatientVisit | No | |
| PreStudy Selection Visit | No | |
| Target Date 12 | No | |
| Target Date 13 | No | |
| Target Date 14 | No |
Leadership
| Role | Staff | Login | Required |
|---|---|---|---|
| Principal | Unger, Jeffrey | JUnger | No |
| Recruiter | - | No | |
| Coordinator | Soler, Daniel | DSoler | No |
| Regulatory | Aguirre, Sandra | SAguirre | No |
Custom Fields
No custom fields.
Sponsor & Organization
| Sponsor | Novo Nordisk |
|---|---|
| Division | Novo Nordisk |
| Team | Novo Nordisk |
| Managing Site | Catalina Research Institute, LLC |
| Organization |
Contacts
| IRB Ref | |
|---|---|
| CRO | |
| CRO Ref | |
| Correspondence | 0 |
Opportunity
| Probability | 0 |
|---|---|
| Comment | |
| Status Color | Gainsboro |
| Currency | - |
